Excalipoint Secures $69M to Advance Cancer Immunotherapy
Excalipoint has captured global attention by raising approximately $69 million to advance its cutting-edge cancer therapies. The Chinese biotech startup focuses on next-generation T-cell engagers, a promising approach in immunotherapy.…